Patients with hematologic malignancies face significantly higher short- and long-term risk for cardiovascular disease vs the general public.

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference ...

In recent years, hematological malignancies have been fundamentally redefined at the molecular level. Disease classification has shifted from morphology-based frameworks to biologically precise ...

Another disease-related barrier relates to the cytopenias experienced by many patients with HMs because of their disease or its treatment. Treatment of anemia and thrombocytopenia consists mainly of ...

- Nine abstracts across Takeda’s hematology portfolio and pipeline demonstrate Takeda’s commitment to patient-centric, innovative care that aims to drive greater treatment outcomes - Includes data ...

Jennifer Vidrine, MBBS, MRCP, of Newcastle upon Tyne Hospitals, stresses the importance of providing personalized, beneficial end-of-life care for patients with hematologic diseases. Jennifer Vidrine, ...

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases. Improving end-of-life care for pediatric ...

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell ...

TAMPA, FL, UNITED STATES, January 15, 2025 /EINPresswire.com/ -- San Rocco Therapeutics announces the GLOBAL HEMATOLOGICAL RARE DISEASES ALLIANCE hosts a 2-day ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA ...